- Titre
- Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial
- Créateurs - sans rôle
- Stefan Hagel - Jena, Germany Jena, GermanySandra Fiedler - Jena, GermanyAndreas Hohn - Cologne, GermanyAlexander Brinkmann - Department of Anaesthesiology and Intensive Care Medicine, General Hospital of Heidenheim, Heidenheim, GermanyOtto R. Frey - Department of Pharmacy, General Hospital of Heidenheim, Heidenheim, GermanyHeike Hoyer - Jena, GermanyPeter Schlattmann - Jena, GermanyMichael Kiehntopf - Jena, Germany Jena, Germany Jena, GermanyJason A. Roberts - Brisbane, Australia Brisbane, AustraliaMathias W. Pletz - Jena, Germanyon behalf of the TARGET Study Group
- Détails de publication
- Trials, Vol.20(1), pp.330-10
- Éditeur
- BioMed Central
- Note de subvention
- 01EO1502 / ;
- Identifiants
- 99153970309311
- Unité académique
- Initial MAnagement & prevent of acute orGan failures IN critically ill patiEnts - IMAGINE
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial
Trials, Vol.20(1), pp.330-10
06/06/2019
PMID: 31171029
Indicateurs
1 Consultations de la notice